Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients (MAESTRO)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00444275
First received: March 5, 2007
Last updated: November 14, 2012
Last verified: November 2012
  Purpose

To compare the efficacy of three different long-term treatment strategies of reflux disease in primary care setting.


Condition Intervention Phase
GERD
Drug: esomeprazole (Nexium®)
Drug: Xolaam®
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open, Parallel-group Study to Evaluate the Efficacy of Three Different Patient Management Strategies During a 12 Weeks Maintenance Phase Following an Initial 4-weeks Acute Treatment Phase in Subjects With Symptoms Thought to be GERD Related

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Efficacy of Three Strategies of Long-term Treatment [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Percentage of failure of maintenance treatment between V2 (4 weeks) and V3 (16 weeks) evaluated by the patient, defined based on responses to 2 questions (if at least 1 negative response was given, the patient was considered to be in failure) : Did the treatment produce sufficient control of reflux symptoms? Do you wish to continue the treatment?


Secondary Outcome Measures:
  • Difference in Symptom Severity Evaluation Performed by the Investigators, When Symptom Severity is Assessed With and Without Reflux Disease Questionnaire (RDQ). [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

    Total percentage of subjects for whom evaluation of symptom severity using the Reflux Disease Questionnaire (RDQ) is different, either positively or negatively, as compared to clinical judgment made by Investigator.

    The RDQ Includes 12 Items: 6 Concern the Frequency of Symptoms Ranging From "Never" for the Lowest Frequency to "Every Day" for the Highest, 6 Others Assess the Severity of Symptoms From "Not at All" to "Strong". The Total Score of the RDQ, Ranging From 0 to 40, is Obtained by Adding the Scores of Each Item.


  • Impact of Treatment With Low Dose Aspirin (Acetyl Salicylic Acid) Used Concomitantly During the Initial Phase and the Maintenance Phase [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    No possibility to describe as only 2 patients took ASA

  • Differences Among Strategies of Maintenance Treatment for Satisfaction of the Patient, Using the GIS (Gord Impact Scale) Scale.(Change in Values of Score Derived From the GIS Questionnaire From V2 to V3 = Start to End of the Maintenance Phase) [ Time Frame: 4 to 16 weeks ] [ Designated as safety issue: No ]
    Change in values of upper digestive symptoms (GORD Impact Scale) from week 4 to week 16. Scale of 1 to 4 : 1 = every day, 2 = often, 3 = sometime, 4 = never)

  • Impact of Anxiety and Depression During the Initial Visit Measured by the HADS ( Hospital Anxiety and Depression Scale) Questionnaire on Response to Initial Treatment and to Maintenance Treatment [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Failure of treatment (as defined as in primary outcome measure) according to confirmed anxiety and depression during maintenance treatment evaluated by the patient via the score of HADS questionnaire. HADS scale ranges= 0 to 21 (the higher score, the worse : ≤7 : no anxiety-depression/ [8-10] : possible anxiety-depression/ >10 : anxiety-depression)

  • Number of Participants and Type of Serious Adverse Events and Adverse Events Leading to a Premature Discontinuation of the Study [ Time Frame: 12 weeks - maintenance treatment phase ] [ Designated as safety issue: No ]
    Number of participants with serious adverse events and adverse events leading to study treatment discontinuation. AE and SAE as defined in ICH-GCP.

  • Score Abacuses Based on the Reflux Disease Questionnaire (RDQ) Questionnaire [ Time Frame: Day 0 ] [ Designated as safety issue: No ]
    May be used to evaluate the severity of symptoms during the initial visit. Not done

  • Score Abacuses Based on the Reflux Disease Questionnaire (RDQ) Questionnaire [ Time Frame: Day 0 ] [ Designated as safety issue: No ]

    May be used to offer patients a strategy of treatment during the initial phase and in the long term.

    Not done


  • Score Abacuses Based on the Reflux Disease Questionnaire (RDQ) [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
    May be used to define the success of treatment. Not done


Enrollment: 3029
Study Start Date: March 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Esomeprazole 20 mg Once Daily (initial phase) Drug: esomeprazole (Nexium®)

This randomized study was conducted on parallel groups and included two phases:

  • One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision
  • One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
Experimental: Esomeprazole 40 mg Once Daily (initial phase) Drug: esomeprazole (Nexium®)

This randomized study was conducted on parallel groups and included two phases:

  • One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision
  • One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
Experimental: Esomeprazole 20 mg Once Daily (Maintenance Phase) Drug: esomeprazole (Nexium®)

This randomized study was conducted on parallel groups and included two phases:

  • One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision
  • One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
Experimental: Esomeprazole 20 mg on Demand (Maintenance Phase) Drug: esomeprazole (Nexium®)

This randomized study was conducted on parallel groups and included two phases:

  • One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision
  • One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
Experimental: Antacid Treatment (Maintenance Phase) Drug: Xolaam®

This randomized study was conducted on parallel groups and included two phases:

  • One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision
  • One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who seek medical advice in primary care for symptoms thought to be GERD related (GERD is a condition which develops when the reflux of stomach content causes troublesome symptoms and / or complications).

Exclusion Criteria:

  • Subjects with any clinical GERD treatment (PPI, H2-receptor antagonists) within the last 3 months prior to Visit 1.
  • A history of severe esophagitis or known other complications, with alarm symptoms
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00444275

Locations
France
Research Site
Rouen, France
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca France Medical Director, MD AstraZeneca
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00444275     History of Changes
Other Study ID Numbers: D9612L00111, EudraCT No: 2006-002867-19
Study First Received: March 5, 2007
Results First Received: March 29, 2010
Last Updated: November 14, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by AstraZeneca:
Gastroesophageal Reflux Disease
Acid Reflux

Additional relevant MeSH terms:
Esomeprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 22, 2014